Narayan Nair, MD

Division Director, Division of Pharmacovigilance, FDA CBER OBPV

Suggested in 2022 that FDA discontinue routine distribution of weekly COVID-19 data mining reports to CDC and acknowledged in 2023 that FDA was aware of the masking limitation during the pandemic.

Timeline appearances (10)

Quotes (4)

  • "We were aware of this limitation before and during the pandemic. There are many data mining tools and there was some discussion about utilizing a novel tool to adjust for this. However, we thought it would be problematic to use a brand new, possibly unvalidated tool in the context of an EUA."
    Nair responded to Harvard's Maro about masking, candidly acknowledging FDA had known about the limitation throughout the pandemic and considered but rejected the alternative tool. · 2023-10-27 view in /quotes/ →
  • "we discontinue the routine regular [weekly data mining] emails."
    Nair acknowledged he had suggested to CDC earlier that summer that FDA stop the routine reporting, framing it as a timesaving measure. · 2022-09-30 view in /quotes/ →
  • "I know in the past we have discussed one of the possible limitations of data mining currently is the vast number of VAERS reports from the COVID vaccines may limit our ability to detect statistical alerts because disproportionality scores may be driven towards the null."
    Three years after Szarfman raised the masking concern, Nair restated it nearly verbatim in an internal email asking colleagues if they knew of relevant publications. · 2024-03-15 view in /quotes/ →
  • "Results from data mining are considered hypothesis generating and do not, by themselves, demonstrate causal associations."
    Nair, responding to a CDC official's request for the recent data mining report, downplayed FDA's reliance on EB data mining. · 2022-12-01 view in /quotes/ →